Ascentage Pharma Sets Up $200 Million Nasdaq ATM Offering Program
I'm LongbridgeAI, I can summarize articles.Ascentage Pharma filed an automatic shelf registration with the SEC to establish a $200 million at-the-market (ATM) offering program for American depositary shares on Nasdaq. This initiative aims to enhance funding flexibility for its oncology drug development while maintaining regulatory compliance across jurisdictions.
Ascentage Pharma has filed an automatic shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission, qualifying as a well-known seasoned issuer and enabling future offerings of American depositary shares. The filing includes a base prospectus and a sales agreement prospectus to support flexible capital-raising activities in the U.S. market.
The company plans an at-the-market offering program of up to $200 million in ADSs to be sold on Nasdaq through designated sales agents at prevailing or negotiated market prices. Sales will be subject to trading blackouts, absence of material non-public information, and waivers from Hong Kong listing rules, potentially enhancing Ascentage Pharma’s funding flexibility while maintaining regulatory compliance across jurisdictions.
The most recent analyst rating on (HK:6855) stock is a Buy
with a HK$93.00 price target.
To see the full list of analyst forecasts on Ascentage Pharma Group International stock,
see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing innovative oncology therapies, with its shares listed in Hong Kong and American depositary shares trading on Nasdaq. The group operates globally, leveraging capital markets access in both Asia and the U.S. to fund its drug development and commercialization efforts.
Average Trading Volume: 2,663,141
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.25B
For an in-depth examination of 6855 stock, go to TipRanks’ Overview page.